

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference

November 23, 2021

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- <u>Kiniksa Pharmaceuticals, Ltd.</u> (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 12:10 p.m. Eastern Time.

A live webcast of Kiniksa's presentation will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST [®] (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!®

Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com